TrialHeadache2022

Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.

Richard B Lipton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.